The poor prognosis of TP53‐mutated MCL has been previously demonstrated in large patient cohorts from Nordic Lymphoma Group “MCL2/MCL3” [12] and FIL “MCL0208” [13] clinical trials. The gene discussed is TP53; the disease is mantle cell lymphoma.